Shoulder Innovations Inc. reported an insider purchase by its CEO and Executive Chairman, Robert Joseph Ball, who acquired 2,200 shares of the company's common stock on March 13, 2026. The shares were purchased at a weighted average price of $15.1782, bringing the aggregate value of the transaction to $33,392.
The reported purchase price per share varied within a specified band from $14.80 to $15.50. After completing this acquisition, Ball's direct ownership of Shoulder Innovations common stock stands at 278,866 shares.
Investors seeking a deeper look at Shoulder Innovations' financials and valuation can consult the detailed Pro Research Report, which covers SI along with more than 1,400 other U.S. equities on InvestingPro.
Quarterly performance and market reaction
The insider purchase comes in the wake of the company's fourth-quarter 2025 financial disclosure. Shoulder Innovations posted revenue of $14.4 million for the quarter, representing a 65% increase year over year. Despite the substantial top-line growth, the company recorded a net loss of $7.8 million for the period.
Market analysts responded to the results with upward revisions to price targets. Jefferies raised its target to $21.00 and kept a Buy rating, highlighting a sales beat and a 62% increase in implant growth. BTIG also lifted its price target to $24.00 and maintained a Buy rating, noting that reported revenue surpassed both its own estimate and consensus expectations.
BTIG's commentary acknowledged the company reported a loss per share of $0.38 for the quarter - a figure that was modestly higher than BTIG's internal estimate but below consensus. The firm emphasized that the underlying drivers of the quarter included ongoing utilization gains and new surgeon adoption, with average selling prices remaining steady.
Context for the insider trade
The purchase by the company's CEO adds to his direct equity stake and occurs alongside evidence of accelerating revenue and expanding implant utilization. The combination of insider buying and analyst target increases illustrates investor and analyst focus on Shoulder Innovations' commercial momentum, even as the company continues to operate at a quarterly loss.
Readers should note that the information above reflects the figures and commentary disclosed by the company and the two named brokerages. The Pro Research Report is available for those who want further detail on SI's valuation and comparative metrics across a broad set of U.S. stocks.